BVNXF (Bioventix) Cyclically Adjusted PS Ratio: (As of Aug. 23, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BVNXF Bioventix PLC BVNXF
57 GF Score
Price $14.71
GF Value $30.35
! 3 Warning Signs
View Full Analysis

What is Bioventix Cyclically Adjusted PS Ratio?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted PS Ratio for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Bioventix  (OTCPK:BVNXF) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Bioventix Cyclically Adjusted PS Ratio Related Terms


Bioventix Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Bioventix's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bioventix Cyclically Adjusted PS Ratio Chart

Bioventix Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 29.97 21.61 20.42 20.92 11.86

Bioventix Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 20.92 0.00 11.86 0.00

BVNXF vs VRTX, REGN, RVMD: Cyclically Adjusted PS Ratio Comparison

For the Biotechnology subindustry, Bioventix's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bioventix Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bioventix's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Bioventix's Cyclically Adjusted PS Ratio falls into.


BVNXF
57GF Score
Bioventix PLC BVNXF
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bioventix Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Bioventix's Cyclically Adjusted Revenue per Share for the fiscal year that ended in Jun25 is calculated as:

For example, Bioventix's adjusted Revenue per Share data for the fiscal year that ended in Jun25 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun25 (Change)*Current CPI (Jun25)
=3.362/138.4000*138.4000
=3.362

Current CPI (Jun25) = 138.4000.

Bioventix Annual Data

Revenue per Share CPI Adj_RevenuePerShare
201606 1.524 101.000 2.088
201706 1.785 103.500 2.387
201806 2.226 105.900 2.909
201906 2.252 107.900 2.889
202006 2.472 108.800 3.145
202106 2.914 111.400 3.620
202206 2.744 120.500 3.152
202306 3.059 129.400 3.272
202406 3.268 133.000 3.401
202506 3.362 138.400 3.362

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Bioventix (BVNXF) Overvalued in 2026?

Based on GuruFocus' analysis, Bioventix stock appears to be undervalued. The current stock price of $14.71 is trading 51.5% below its estimated GF Value™ of $30.35.

Key valuation signals for BVNXF:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: $30.35 vs. price of $14.71 (51.5% below fair value)
  • GF Score™: 57/100 with 3 warning signs

No single metric tells the full story. See the BVNXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Bioventix Business Description

Other Exchanges BVXP:UK51B:Germany
Address 27-28 Eastcastle Street, London, GBR, W1W 8DH
Bioventix PLC is a biotechnology company based in the United Kingdom. It specializes in the creation and supply of high-affinity sheep monoclonal antibodies and clinical diagnostics and drug abuse testing. The company's portfolio of products includes drugs that are applicable in the areas of cardiology, fertility, infectious diseases, Thyroid, and vitamin D disorder among others. It earns maximum revenue from European country.
57GF Score

Get the complete analysis for BVNXF

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$14.71
Price
$30.35
GF Value